Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions.
about
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.Current progress in innovative engineered antibodies.In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy.Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice.Engineered Sialylation of Pathogenic Antibodies In Vivo Attenuates Autoimmune Disease.GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity.Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity.Novel drug and soluble target tolerant antidrug antibody assay for therapeutic antibodies bearing the P329G mutation.The burgeoning antibody landscape.Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma.Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection.Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model
P2860
Q37741534-7C6942D7-EC20-42EB-B43A-4518C8EAEAFAQ40077818-27BE46D2-D74A-4F76-A12A-016902B5502AQ40218347-A92C385A-91A7-4327-943A-554773485A28Q46330101-7A210DCC-AA8D-4665-9B0B-A93D950E4FDCQ47220975-4802646C-552A-446A-B6DF-22123DCA6124Q49168895-07078302-BAB6-43DC-870A-B0EE0A7C525FQ50045161-4CAC4FFC-6CDD-4665-A32D-B51F4D4CEE4DQ50995227-45F177E0-2617-46FC-B4FB-A34586CCA4E8Q51458033-36D433A8-FB61-4980-900A-99DC81CA0915Q52719493-24C2CCB4-0725-480B-B056-7FE9C4324D47Q54217627-46057167-4F89-4E1A-BFBA-D33547751334Q58569620-0420F33B-A126-4442-B51C-F3E28088A6A5
P2860
Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Novel human IgG1 and IgG4 Fc-e ...... hed immune effector functions.
@en
type
label
Novel human IgG1 and IgG4 Fc-e ...... hed immune effector functions.
@en
prefLabel
Novel human IgG1 and IgG4 Fc-e ...... hed immune effector functions.
@en
P2093
P2860
P356
P1476
Novel human IgG1 and IgG4 Fc-e ...... hed immune effector functions.
@en
P2093
Christian Klein
Christian Spick
Claudia Ferrara Koller
Ekkehard Mössner
Manfred Kubbies
Pablo Umaña
Sandra Grau-Richards
Sylvia Herter
Tilman Schlothauer
Virginie Steinhart
P2860
P304
P356
10.1093/PROTEIN/GZW040
P577
2016-08-29T00:00:00Z